Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.76 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.76 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.76 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.76 |
| ▸ | HRH2 | P25021 | 2/20 | 0.76 |
| ▸ | HTR2A | P28223 | 2/20 | 0.76 |
| ▸ | HTR2C | P28335 | 2/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.76 |
| ▸ | HRH1 | P35367 | 2/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.76 |
| ▸ | DRD3 | P35462 | 2/20 | 0.76 |
| ▸ | HTR2B | P41595 | 2/20 | 0.76 |
| ▸ | HTR6 | P50406 | 2/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25375446 | 0.90 | CYP2D6 (0.68) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL4669319 | 0.90 | CYP2D6 (0.68) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL8105789 | 0.87 | CYP2D6 (0.64) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| Orphenadrine SCHEMBL119471 | 0.87 | SLC6A2 (1.00) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| Orphenadrine SCHEMBL29359844 | 0.87 | SLC6A2 (1.00) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| Orphenadrine SCHEMBL28727 | 0.87 | SLC6A2 (1.00) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| Tofenacin SCHEMBL49290 | 0.87 | CYP2D6 (0.64) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| Tofenacin SCHEMBL637494 | 0.85 | LMNA (0.65) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| Orphenadrine SCHEMBL30903909 | 0.85 | LMNA (1.00) | CYP2D6CHRM2CHRM4CHRM5ADRA2A | |
| Orphenadrine SCHEMBL1235378 | 0.85 | LMNA (1.00) | CYP2D6CHRM2CHRM4CHRM5ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930308-A1 | Pharmaceutical agents for the treatment of cerebral amyloidosis | NYMOX CORPORATION (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-0983222-B1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 2007-11-28 | — | — | EP | disclosed |
| US-6518314-B1 | For treating cerebral amyloidosis; compounds that impede the transformation of dense microspheres (DMS) into amyloid | NYMOX CORPORATION (CA) | 2003-02-11 | — | — | US | disclosed |
| US-6130221-A | ALZHEIMERS | NYMOX CORPORATION (CA) | 2000-10-10 | — | — | US | disclosed |
| EP-0983222-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052898-A9 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998052898-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 1998-11-26 | — | — | WO | disclosed |